Talzenna 0.25 mg hard capsules
Sponsors
UZ Leuven, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Medica Scientia Innovation Research S.L., Fundacion Oncosur
Conditions
Advanced solid tumorMetastatic hormone–naïve prostate cancer (mHNPC)Multiple myelomaNon-Hodgkin lymphomaOligoprogressive metastatic castration-refractory prostate cancerProstate CancerT-cell prolymphocytic leukemia
Phase 2
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
A multicenter, open label, randomized phase II trial to evaluate the efficacy of Talazoparib plus Enzalutamide as first line treatment for patients with Metastatic castration resistant Prostate Cancer following progression on Abiraterone.
RecruitingCTIS2023-510536-37-00
Start: 2024-07-05Target: 103Updated: 2025-09-05
“A randomized phase II trial to evaluate the antitumor activity of
Enzalutamide and Talazoparib (PF-06944076) for the treatment of metastatic hormone-naïve prostate
cancer”
CompletedCTIS2023-509387-24-00
Start: 2020-09-02End: 2025-05-06Target: 54Updated: 2025-05-05